DelveInsight Business Research LLP

DelveInsight’s, “Non-Small Cell Lung Cancer (NSCLC) – Pipeline Insights, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.

Click here to read more.

The three main histological subtypes of Non-Small Cell Lung Cancer are:

• Adenocarcinoma: About 40% of all lung cancers are adenocarcinomas. These tumours start in mucus-producing cells that line the airways.
• Squamous cell carcinoma (SCC): About 25-30% of all lung cancers are Squamous cell carcinoma. This type of cancer develops in cells that line the airways and is usually caused by smoking.
• Large cell (undifferentiated) carcinoma: This type makes up around 10-15% of all lung cancers. It gets its name from the way that the cancer cells look when they are examined under a microscope.

Read more about the Non-small Cell lung cancer pipeline report.

NSCLC Emerging Therapies:

• Canakinumab: Novartis
• Cemiplimab (Libtayo)- Regeneron Pharmaceuticals/Sanofi

Request for sample pages: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight

Table of contents:

1. Introduction
2. Executive Summary
3. Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Non-Small Cell Lung Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Avelumab: Merck
11. Mid Stage Products (Phase II)
12. Eftilagimod: Immutep Limited
13. Poziotinib: Hanmi Pharmaceutical Company Limited
14. Early Stage Products (Phase I)
15. DZD 9008: Dizal Pharmaceutical
16. TY-9591: TYK Medicines, Inc.
17. Pre-clinical and Discovery Stage Products
18. Inactive Products
19. Non-Small Cell Lung Cancer Key Companies
20. Non-Small Cell Lung Cancer Key Products
21. Non-Small Cell Lung Cancer- Unmet Needs
22. Non-Small Cell Lung Cancer- Market Drivers and Barriers
23. Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
24. Non-Small Cell Lung Cancer Analyst Views
25. Non-Small Cell Lung Cancer Key Companies
26. Appendix

Download report: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/